David Hanzel

David Hanzel is a versatile scientist and entrepreneur with extensive experience in biotechnology and life sciences. He is currently involved with PRAV Biosciences, where he is working on validating a novel pan-respiratory antiviral therapeutic.1

Professional Background

David Hanzel's career spans several decades and includes roles in various biotechnology companies and venture capital firms:

Current Roles::

• Sole Proprietor at David Hanzel Consulting (since April 2013)
• Involved with PRAV Biosciences (fundraising and therapeutic validation)

Previous Positions::

• Consulting Scout at Alcon Seed Fund (September 2022 - March 2023)
• Partner at X/Seed Capital Management (September 2006 - April 2013)
• VP Marketing at Pacific Biosciences (July 2004 - April 2006)
• Principal Scientist at Molecular Dynamics / Amersham / General Electric Healthcare (September 1991 - June 2004)

Expertise and Skills

David Hanzel's expertise is broad and multidisciplinary, including:

• Scientific management
• Cell, molecular, and synthetic biology
• Physiology
• Protein, synthetic, and surface chemistry
• Opto-mechanical instrumentation
• Imaging
• Software development
• Clinical studies
• Product marketing
• Intellectual property

He describes himself as "Translating Science, Enabling Technology," reflecting his ability to bridge scientific innovation and practical applications.1

Current Focus

At PRAV Biosciences, David is currently focused on fundraising to validate a novel pan-respiratory antiviral therapeutic. He is open to help and ideas in this endeavor.1

Approach and Philosophy

David Hanzel particularly enjoys working with focused entrepreneurs to tackle significant technical opportunities that enable large markets. His goal is to help companies avoid repeating mistakes and to make only original ones, emphasizing the importance of learning from experience.1

Throughout his career, David has been involved in various aspects of biotechnology, from early-stage research to product development and commercialization. His diverse background allows him to contribute to multiple facets of scientific and business development in the life sciences sector.